Characterization of intertypic recombinants of the Epstein-Barr virus from the body-cavity-based lymphomas cell lines BC-1 and BC-2.
Virology.
1999 Nov 25;264(2):359-69. doi: 10.1006/viro.1999.0015. PubMed PMID:
10562498.
Epstein-Barr virus recombinants from BC-1 and BC-2 can immortalize human primary B lymphocytes with different levels of efficiency and in the absence of coinfection by Kaposi's sarcoma-associated herpesvirus.
J Virol.
2000 Jan;74(2):735-43. doi: 10.1128/jvi.74.2.735-743.2000. PubMed PMID:
10623735; PubMed Central PMCID:
PMC111593.
Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis.
Nature.
2001 Sep 6;413(6851):86-91. doi: 10.1038/35092592. PubMed PMID:
11544531.
Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma.
Genes Dev.
2003 Dec 15;17(24):3112-26. doi: 10.1101/gad.1158703. Epub 2003 Dec 17. PubMed PMID:
14681207; PubMed Central PMCID:
PMC305262.
High-resolution characterization of the pancreatic adenocarcinoma genome.
Proc Natl Acad Sci U S A.
2004 Jun 15;101(24):9067-72. doi: 10.1073/pnas.0402932101. PubMed PMID:
15199222; PubMed Central PMCID:
PMC428474.
High-resolution global profiling of genomic alterations with long oligonucleotide microarray.
Cancer Res.
2004 Jul 15;64(14):4744-8. doi: 10.1158/0008-5472.CAN-04-1241. PubMed PMID:
15256441.
Common and contrasting genomic profiles among the major human lung cancer subtypes.
Cold Spring Harb Symp Quant Biol.
2005;70:11-24. doi: 10.1101/sqb.2005.70.021. PubMed PMID:
16869734.
High-resolution genomic profiles of human lung cancer.
Proc Natl Acad Sci U S A.
2005 Jul 5;102(27):9625-30. doi: 10.1073/pnas.0504126102. Epub 2005 Jun 27. PubMed PMID:
15983384; PubMed Central PMCID:
PMC1160520.
Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse.
Proc Natl Acad Sci U S A.
2006 Apr 11;103(15):5947-52. doi: 10.1073/pnas.0601273103. Epub 2006 Apr 3. PubMed PMID:
16585505; PubMed Central PMCID:
PMC1458678.
Genomic alterations link Rho family of GTPases to the highly invasive phenotype of pancreas cancer.
Proc Natl Acad Sci U S A.
2008 Dec 9;105(49):19372-7. doi: 10.1073/pnas.0809966105. Epub 2008 Dec 2. PubMed PMID:
19050074; PubMed Central PMCID:
PMC2614768.
ARID1B is a specific vulnerability in ARID1A-mutant cancers.
Nat Med.
2014 Mar;20(3):251-4. doi: 10.1038/nm.3480. Epub 2014 Feb 23. PubMed PMID:
24562383; PubMed Central PMCID:
PMC3954704.
Characterizing genomic alterations in cancer by complementary functional associations.
Nat Biotechnol.
2016 May;34(5):539-46. doi: 10.1038/nbt.3527. Epub 2016 Apr 18. PubMed PMID:
27088724; PubMed Central PMCID:
PMC4868596.
Genomic Copy Number Dictates a Gene-Independent Cell Response to CRISPR/Cas9 Targeting.
Cancer Discov.
2016 Aug;6(8):914-29. doi: 10.1158/2159-8290.CD-16-0154. Epub 2016 Jun 3. PubMed PMID:
27260156; PubMed Central PMCID:
PMC4972686.
Functional Genomic Characterization of Cancer Genomes.
Cold Spring Harb Symp Quant Biol.
2016;81:237-246. doi: 10.1101/sqb.2016.81.031070. Epub 2016 Nov 4. Review. PubMed PMID:
27815544.
An Educational and Administrative Intervention to Promote Rational Laboratory Test Ordering on an Academic General Medicine Service.
Am J Med.
2017 Jan;130(1):47-53. doi: 10.1016/j.amjmed.2016.08.021. Epub 2016 Sep 9. PubMed PMID:
27619354; PubMed Central PMCID:
PMC6598201.
KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer.
Elife.
2017 Feb 1;6. doi: 10.7554/eLife.18970. PubMed PMID:
28145866; PubMed Central PMCID:
PMC5305212.
ATXN1L, CIC, and ETS Transcription Factors Modulate Sensitivity to MAPK Pathway Inhibition.
Cell Rep.
2017 Feb 7;18(6):1543-1557. doi: 10.1016/j.celrep.2017.01.031. PubMed PMID:
28178529; PubMed Central PMCID:
PMC5313047.
PIK3CA mutant tumors depend on oxoglutarate dehydrogenase.
Proc Natl Acad Sci U S A.
2017 Apr 25;114(17):E3434-E3443. doi: 10.1073/pnas.1617922114. Epub 2017 Apr 10. PubMed PMID:
28396387; PubMed Central PMCID:
PMC5410781.
Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway.
Nature.
2017 Jul 27;547(7664):453-457. doi: 10.1038/nature23007. Epub 2017 Jul 5. PubMed PMID:
28678785; PubMed Central PMCID:
PMC5667900.
Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma.
Cancer Cell.
2017 Aug 14;32(2):185-203.e13. doi: 10.1016/j.ccell.2017.07.007. PubMed PMID:
28810144; PubMed Central PMCID:
PMC5964983.
Decomposing Oncogenic Transcriptional Signatures to Generate Maps of Divergent Cellular States.
Cell Syst.
2017 Aug 23;5(2):105-118.e9. doi: 10.1016/j.cels.2017.08.002. PubMed PMID:
28837809; PubMed Central PMCID:
PMC5639711.
Aspirin exerts high anti-cancer activity in PIK3CA-mutant colon cancer cells.
Oncotarget.
2017 Oct 20;8(50):87379-87389. doi: 10.18632/oncotarget.20972. eCollection 2017 Oct 20. PubMed PMID:
29152088; PubMed Central PMCID:
PMC5675640.
Correction: KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer.
Elife.
2017 Oct 31;6. doi: 10.7554/eLife.33173. PubMed PMID:
29087937; PubMed Central PMCID:
PMC5663476.
Advances in the Genetics and Biology of Pancreatic Cancer.
Cancer J.
2017 Nov/Dec;23(6):315-320. doi: 10.1097/PPO.0000000000000286. Review. PubMed PMID:
29189326.
Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer.
Science.
2017 Dec 15;358(6369):1443-1448. doi: 10.1126/science.aal5240. Epub 2017 Nov 23. PubMed PMID:
29170280; PubMed Central PMCID:
PMC5823247.
Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma.
JAMA Oncol.
2018 Mar 8;4(3):e173420. doi: 10.1001/jamaoncol.2017.3420. Epub 2018 Mar 8. PubMed PMID:
29098284; PubMed Central PMCID:
PMC5844844.
Synthetic Lethal Vulnerabilities in KRAS-Mutant Cancers.
Cold Spring Harb Perspect Med.
2018 Aug 1;8(8). doi: 10.1101/cshperspect.a031518. Review. PubMed PMID:
29101114; PubMed Central PMCID:
PMC5990478.
Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer.
Cancer Discov.
2018 Sep;8(9):1112-1129. doi: 10.1158/2159-8290.CD-18-0349. Epub 2018 May 31. PubMed PMID:
29853643; PubMed Central PMCID:
PMC6125219.
Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine.
Cancer Discov.
2018 Sep;8(9):1096-1111. doi: 10.1158/2159-8290.CD-18-0275. Epub 2018 Jun 14. PubMed PMID:
29903880; PubMed Central PMCID:
PMC6192263.
Assessing Therapeutic Efficacy of MEK Inhibition in a KRASG12C-Driven Mouse Model of Lung Cancer.
Clin Cancer Res.
2018 Oct 1;24(19):4854-4864. doi: 10.1158/1078-0432.CCR-17-3438. Epub 2018 Jun 26. PubMed PMID:
29945997; PubMed Central PMCID:
PMC6482448.
Mutational processes shape the landscape of TP53 mutations in human cancer.
Nat Genet.
2018 Oct;50(10):1381-1387. doi: 10.1038/s41588-018-0204-y. Epub 2018 Sep 17. PubMed PMID:
30224644; PubMed Central PMCID:
PMC6168352.
iRGD-guided Tumor-penetrating Nanocomplexes for Therapeutic siRNA Delivery to Pancreatic Cancer.
Mol Cancer Ther.
2018 Nov;17(11):2377-2388. doi: 10.1158/1535-7163.MCT-17-1090. Epub 2018 Aug 10. PubMed PMID:
30097486; PubMed Central PMCID:
PMC6298224.
Refining Classification of Pancreatic Cancer Subtypes to Improve Clinical Care.
Gastroenterology.
2018 Dec;155(6):1689-1691. doi: 10.1053/j.gastro.2018.11.004. Epub 2018 Nov 9. PubMed PMID:
30419209.
Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer.
Genet Med.
2019 Jan;21(1):213-223. doi: 10.1038/s41436-018-0009-5. Epub 2018 Jul 2. PubMed PMID:
29961768; PubMed Central PMCID:
PMC6666401.
Oncogenic NRG1 Fusions: A New Hope for Targeted Therapy in Pancreatic Cancer.
Clin Cancer Res.
2019 Aug 1;25(15):4589-4591. doi: 10.1158/1078-0432.CCR-19-1280. Epub 2019 Jun 4. PubMed PMID:
31164372; PubMed Central PMCID:
PMC6679796.
Isoform-Specific Destabilization of the Active Site Reveals a Molecular Mechanism of Intrinsic Activation of KRas G13D.
Cell Rep.
2019 Aug 6;28(6):1538-1550.e7. doi: 10.1016/j.celrep.2019.07.026. PubMed PMID:
31390567; PubMed Central PMCID:
PMC6709685.
Synthetic Lethal Interaction of SHOC2 Depletion with MEK Inhibition in RAS-Driven Cancers.
Cell Rep.
2019 Oct 1;29(1):118-134.e8. doi: 10.1016/j.celrep.2019.08.090. PubMed PMID:
31577942; PubMed Central PMCID:
PMC6918830.
Atypical KRASG12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer.
Cancer Discov.
2020 Jan;10(1):104-123. doi: 10.1158/2159-8290.CD-19-1006. Epub 2019 Oct 24. PubMed PMID:
31649109; PubMed Central PMCID:
PMC6954322.
CDK7 Inhibition Potentiates Genome Instability Triggering Anti-tumor Immunity in Small Cell Lung Cancer.
Cancer Cell.
2020 Jan 13;37(1):37-54.e9. doi: 10.1016/j.ccell.2019.11.003. Epub 2019 Dec 26. PubMed PMID:
31883968; PubMed Central PMCID:
PMC7277075.
Structure-Based Design of a Potent and Selective Covalent Inhibitor for SRC Kinase That Targets a P-Loop Cysteine.
J Med Chem.
2020 Feb 27;63(4):1624-1641. doi: 10.1021/acs.jmedchem.9b01502. Epub 2020 Jan 30. PubMed PMID:
31935084; PubMed Central PMCID:
PMC7493195.
Defining and Targeting Adaptations to Oncogenic KRASG12C Inhibition Using Quantitative Temporal Proteomics.
Cell Rep.
2020 Mar 31;30(13):4584-4599.e4. doi: 10.1016/j.celrep.2020.03.021. PubMed PMID:
32234489.
Discovery of a selective inhibitor of doublecortin like kinase 1.
Nat Chem Biol.
2020 Jun;16(6):635-643. doi: 10.1038/s41589-020-0506-0. Epub 2020 Apr 6. PubMed PMID:
32251410; PubMed Central PMCID:
PMC7246176.
High-throughput dynamic BH3 profiling may quickly and accurately predict effective therapies in solid tumors.
Sci Signal.
2020 Jun 16;13(636). doi: 10.1126/scisignal.aay1451. PubMed PMID:
32546544; PubMed Central PMCID:
PMC8023011.
Biomarker-Guided Development of DNA Repair Inhibitors.
Mol Cell.
2020 Jun 18;78(6):1070-1085. doi: 10.1016/j.molcel.2020.04.035. Epub 2020 May 26. Review. PubMed PMID:
32459988; PubMed Central PMCID:
PMC7316088.
Altered RNA Splicing by Mutant p53 Activates Oncogenic RAS Signaling in Pancreatic Cancer.
Cancer Cell.
2020 Aug 10;38(2):198-211.e8. doi: 10.1016/j.ccell.2020.05.010. Epub 2020 Jun 18. PubMed PMID:
32559497; PubMed Central PMCID:
PMC8028848.
Multiplexed single-cell transcriptional response profiling to define cancer vulnerabilities and therapeutic mechanism of action.
Nat Commun.
2020 Aug 27;11(1):4296. doi: 10.1038/s41467-020-17440-w. PubMed PMID:
32855387; PubMed Central PMCID:
PMC7453022.
The Human and Mouse Enteric Nervous System at Single-Cell Resolution.
Cell.
2020 Sep 17;182(6):1606-1622.e23. doi: 10.1016/j.cell.2020.08.003. Epub 2020 Sep 3. PubMed PMID:
32888429; PubMed Central PMCID:
PMC8358727.
Diabetes, Weight Change, and Pancreatic Cancer Risk.
JAMA Oncol.
2020 Oct 1;6(10):e202948. doi: 10.1001/jamaoncol.2020.2948. Epub 2020 Oct 8. PubMed PMID:
32789511; PubMed Central PMCID:
PMC7426876.
Synthetic Lethal Interaction between the ESCRT Paralog Enzymes VPS4A and VPS4B in Cancers Harboring Loss of Chromosome 18q or 16q.
Cell Rep.
2020 Dec 15;33(11):108493. doi: 10.1016/j.celrep.2020.108493. PubMed PMID:
33326793; PubMed Central PMCID:
PMC8374858.
Functional Genomics Identifies Metabolic Vulnerabilities in Pancreatic Cancer.
Cell Metab.
2021 Jan 5;33(1):199-210.e8. doi: 10.1016/j.cmet.2020.10.018. Epub 2020 Nov 4. PubMed PMID:
33152323; PubMed Central PMCID:
PMC7790858.
What would you like to do?